Medical
Pharmaceutical
Health

Aerie Pharmaceuticals

$45.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.22 (0.48%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AERI and other stocks, options, ETFs, and crypto commission-free!

About

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. Read More The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

Employees
353
Headquarters
Durham, North Carolina
Founded
2005
Market Cap
2.08B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
501.67K
High Today
$45.97
Low Today
$44.50
Open Price
$45.96
Volume
184.16K
52 Week High
$74.75
52 Week Low
$32.18

Collections

Medical
Pharmaceutical
Health
Therapy
Technology
2013 IPO

News

Seeking AlphaMar 18

Aerie Pharma launches mid-stage study of AR-1105

Aerie Pharmaceuticals (AERI -0.9% ) initiates a Phase 2 clinical trial evaluating AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion.

47
StreetInsiderMar 18

Aerie Pharma (AERI) Begins Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with RVO

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) today announced the commencement of patient dosing in a Phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This Phase 2 study (AR1105-CS201) will be conducted at approximately 20 centers in the United States and enroll up to 45 patients. The primary objectives of the trial are to evaluate the safety, tolerability and efficacy of the AR-1105 dexamethasone int...

46
Yahoo FinanceMar 13

Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma

Aerie Pharmaceuticals, Inc. (AERI announced that the FDA has approved Rocklatan 0.02%/0.005% to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rocklatan is a once-daily, quadruple-action fixed-dose combination of Rhopressa (netarsudil) and Pfizer’s PFE Xalatan (latanoprost). The FDA approval was supported by data from two phase III registration studies, MERCURY 1 and MERCURY 2. In these studies, Rocklatan achieved its primary 90-day efficacy endpoint...

57

Earnings

-$1.73
-$1.36
-$0.99
-$0.62
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.